图光制药

最新新闻

• Morgan Stanley Maintains MapLight Therapeutics(MPLT.US) With Hold Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $21 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  BMO Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• 评级变动
  UBS Downgrades MapLight Therapeutics(MPLT.US) to Hold Rating, Cuts Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Morgan Stanley Downgrades MapLight Therapeutics(MPLT.US) to Hold Rating, Cuts Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Needham Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Cuts Target Price to $43
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• Guggenheim Initiates MapLight Therapeutics(MPLT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Craig-Hallum Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Cuts Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/7/28
• 评级变动
  Analysts Are Bullish on Top NA Stocks: Safe Pro Group, Inc. (SPAI), MapLight Therapeutics, Inc. (MPLT)
  TipRanks · 2026/7/28
• 评级变动
  MapLight Therapeutics, Inc. (MPLT) Gets a Buy From Jefferies
  TipRanks · 2026/7/30
• 评级变动
  LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Analysts Are Bullish on Top NA Stocks: Syensqo SA/NV (SHBBF), MapLight Therapeutics, Inc. (MPLT)
  TipRanks · 2026/7/28
• 评级变动
  Analysts Offer Insights on NA Companies: CAMP4 Therapeutics Corporation (CAMP), MapLight Therapeutics, Inc. (MPLT) and Andersen Group, Inc. Class A (ANDG)
  TipRanks · 2026/8/14
• 评级变动
  CCORF Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $43
  \u5e02\u573a\u8d44\u8baf · 2026/7/24
• 评级变动
  Analysts' Top NA Picks: Solv Energy (MWH), MapLight Therapeutics, Inc. (MPLT)
  TipRanks · 2026/8/14
• 评级变动
  Morgan Stanley Keeps Their Hold Rating on MapLight Therapeutics, Inc. (MPLT)
  TipRanks · 2026/8/17
• UBS Maintains MapLight Therapeutics(MPLT.US) With Hold Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• UBS Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $52
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Analysts' Top NA Picks: BKV Corporation (BKV), MapLight Therapeutics, Inc. (MPLT)
  TipRanks · 2026/7/22

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。